The biotechnology company Moderna has multiplied its value since the first eruptions in Wuhan. But now at the end of the pandemic, the stock price may need a new booster.
The market value of the biotechnology company Moderna has risen by approx. 700 percent through the pandemic.
Already a subscriber to Aftenposten? Check if you have access to everything from E24
Already a subscriber?
Reference-www.aftenposten.no
